Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets Decision comes two years after acquiring the drug’s parent company, Global Blood Therapeutic, in a $5.4 billion deal By ...

Pfizer has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) approved for treating sickle cell disease (SCD) from worldwide markets. The company is also discontinuing all ...

On Wednesday, Pfizer Inc. (NYSE:PFE) said the company is voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where ...

Oxbryta's withdrawal will be a "significant blow" to patients with sickle cell disease "who have been historically underserved," BMO Capital Markets analyst Evan Seigerman wrote in a research note ...

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

What the withdrawal of its sickle cell drug means for Pfizer, patients, and the FDA. The concerns behind the withdrawal were serious. The Food and Drug Administration approved Oxbryta in 2019, but ...

The benefits of Oxbryta no longer outweigh the risks, Pfizer says. Pfizer yanks sickle-cell treatment worldwide after possible link to deaths. Share. Resize. Listen (2 min) Skip to main content.

SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the Medicines and Healthcare products Regulatory Agency ...

Oxbryta is a prescription drug used to treat sickle cell disease. Learn about the common, mild, and serious side effects it can cause and how to manage them. Health Conditions ...

Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall.

Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period. Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces.

In the second quarter of 2024, Oxbryta generated sales of $92 million, up 20% year-over-year. Pfizer added Oxbryta to its portfolio via its $5.4 billion buyout of Global Blood Therapeutics in 2022.